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ABSTRACT  
 
Duchenne Muscular Dystrophy (DMD), caused by mutations in the 
dystrophin gene, is one of the most severe myopathies. Among 
different therapeutic strategies, exon skipping allows the rescue of 
dystrophin synthesis through the production of a shorter but 
functional mRNA. Making use of exon skipping strategy we 
demonstrated that in DMD, the absence of dystrophin at the 
sarcolemma delocalizes and downregulates Nitric Oxide Synthase 
(nNOS); this alters HDAC2 S-nitrosylation and its chromatin 
association. We show that the differential HDAC2 nitrosylation state 
in Duchenne versus wild-type conditions deregulates the expression 
of a specific subset of microRNA genes crucial in DMD 
physiopathology.  
Namely, we identified miR-1 as regulator of the redox state of the cell 
through modulation of the G6PD enzyme while miR-29 controls the 
fibrotic process targeting extracellular matrix proteins. 
We also show that, at variance with other myomiRs, miR-206 and 
miR-31 escape from the dystrophin-nNOS control being expressed in 
activated satellite cells before dystrophin expression. In these cells, 
miR-206 contributes to muscle regeneration through repression of the 
satellite specific factor Pax7, while miR-31 inhibits the early 
expression of dystrophin by directly repressing its mRNA. 
Finally, in human DMD myoblasts treated with exon skipping 
molecules, we demonstrate that miR-31 inhibition increases 
dystrophin rescue representing a new approach to coadiuvate the 
existing therapeutic strategies.   
 
We conclude that: 
- the pathway activated by dystrophin/nNOS controls key 
miRNA circuitries increasing the robustness of the muscle 
differentiation programme. 
- specific miRNAs are induced during muscle regeneration 
controlling the timing of mRNA expression during myoblasts 
differentiation. 
- the inhibition of specific miRNA extression enhances 
dystrophin rescue obtained through exon skipping treatments. 
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INTRODUCTION 
 
miRNA biogenesis and function 
 
miRNAs are small, evolutionarily conserved noncoding RNAs, 
transcribed by RNA polymerase II. miRNAs display peculiar genic 
organization as they can be intergenic, exonic, intronic as 
monocistrnic or polycistronic units (Morlando et al., 2008; Ballarino 
et al., 2009). 
Pri-miRNAs undergo a first endonucleolitic cleavage by the 
microprocessor complex (Drosha and DGCR8), which produces a 70 
nucleotide hairpin RNA, termed pre-miRNA, which is subsequently 
exported to the cytoplasm and processed by Dicer to yield a duplex 
RNA 22-23 nucleotides long. Only one filament will be subsequently 
loaded into the silencing complex (RISC) as mature miRNA, while 
the other strand, the miRNA* will be degradated (Krol et al., 2010; 
Figure 1). 
miRNAs regulate gene expression through sequence-specific 
interactions with the 3′ untranslated regions (UTRs) of target mRNAs 
resulting in translational repression or mRNA destabilization (Krol et 
al., 2010, Figure 1). The binding specificity to complementary target 
mRNAs is determined by Watson–Crick base-pairing of nucleotides 
2–8 at the 5′ end of the miRNA, referred to as the ‘seed sequence’. 
miRNAs that share the same seed sequence are part of the same 
family and this means that they can act on the same target mRNAs.  
While some miRNAs may exert their effects through pronounced 
repression of a relatively small number of mRNA targets, more 
commonly, miRNAs regulate dozens or hundreds of targets by 
relatively fine changes in expression. Thus, the summation of small 
changes in multiple mRNAs may be responsible for phenotypic 
effects of miRNAs. A recent study also demonstrated the ability of a 
miRNA to enhance translation, raising interesting new possibilities 
for the regulatory actions of miRNAs (Vasudevan et al., 2007) In 
addition, there is also evidence that small RNAs can directly control 
transcription through sequence-specific interactions with promoter 
elements of target genes (Schwartz et al., 2008). Perhaps, miRNAs 
can also function in a similar setting by directly conferring 
transcriptional, and post-transcriptional regulation on target genes. 
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Figure 1: miRNA biogenesis (adapted from Krol et al., 2010) 
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Muscle-specific miRNA and their role in muscle development 
 
Cardiac and skeletal muscle development are controlled by 
evolutionarily conserved networks of transcription factors that 
regulate the expression of genes crucial in coordinating processes like 
muscle growth, morphogenesis, differentiation, and contractility. For 
istance, in cardiac muscle MEF2 and the serum response factor (SRF) 
cooperatively activate cardiac gene expression by association with 
transcriptional co-activators. In skeletal muscle MEF2 activates the 
myogenic differentiation program in association with the basic-helix-
loop-helix (bHLH) transcription factors, MyoD and myogenin 
(Potthoff & Olson, 2007). In addition to coordinate the expression of 
muscle genes, myogenic transcription factors also regulate the 
expression of a collection of microRNAs, which modulate at several 
levels muscle development and function. 
An essential role for miRNAs in muscle development was shown by 
generating conditional null alleles of Dicer in cardiomyocytes and 
skeletal muscle, which results in severe muscle defects. These 
specific phenotipes are due to loss of miRNAs specifically expressed 
in cardiac and skeletal muscle (McCarthy JJ 2008). 	  
Among these, the most widely studied are members of miR-1/206 and 
miR-133a/133b families, which originate from bicistronic transcripts 
(Figure 2) (Chen et al., 2006). miR-1-1 and miR-1-2 are identical and 
differ from miR-206 by four nucleotides, and miR-133a-1 and miR-
133a-2 are identical and differ from miR-133b by two nucleotides. 
Cardiac and skeletal muscle specific transcription of miR-1-1/133a-2 
and miR-1-2/133a-1 in vertebrates is controlled by two separate 
enhancers, one upstream and the other intergenic where the 
coordinated action of myogenic transcription factors SRF, MEF2, and 
MyoD has been reported (Figure 2) (Liu et al., 2007; Rao et al., 2006; 
Zhao et al., 2005).  
The third cluster of muscle-specific miRNAs encoding miR-206 and 
miR-133b is expressed specifically in skeletal muscle (Chen et al., 
2006) and its transcription is controlled by an upstream regulatory 
region enriched for MyoD association (Rao et al., 2006).  
These miRNAs has been demonstrated to promote embryonic stem 
(ES) cells differentiation into mesodermal progenitors (Ivey et al., 
2008) and myoblasts differentiation (Kim et al., 2006). 
In vitro and in vivo studies have demonstrated that miR-1, miR-133a 
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and miR-206 regulate crucial aspects of muscle biology by targeting 
key regulators of muscle differentiation and proliferation (Figure 3 
and reviewed in Williams et al., 2009)  
________________________________________________________ 
 
 
 
Figure 2. miRNA genomic organization (adapted from Williams 
et al., 2009) 
________________________________________________________ 
 
Despite the fact that miR-1 and miR-206 belong to the same family 
an share the same mRNA targets in skeletal muscle, their specific 
action during muscle differentiation has still to be adressed. 
 
Recently, it was discovered that myosin genes encode a new family of 
muscle specific miRNAs, the miR-208 family, which have important 
functions in regulating myosin content and stress-dependent cardiac 
remodeling (van Rooij et al., 2008). 
 
In addition to muscle-specific miRNAs, there are also examples of 
ubiquitously expressed miRNAs that have been shown to have 
functions in muscle physiology like miR-214, miR-138 and miR-181 
(reviewed in Williams et al., 2009).  
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Figure 3. miRNA circuits during skeletal muscle (A) and cardiac 
(B) development (adapted from Williams et al., 2009) 
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miRNA in muscle disease 
 
Several important studies have indicated that miRNA expression is 
dysregulated in cardiac and skeletal muscle disease and, in some 
cases, individual miRNAs have been shown to cause or alleviate 
disease. Global profiling of miRNAs in different forms of human 
heart disease demonstrated that miRNA gene expression signatures 
are diagnostic for distinct but related forms of heart disease (Ikeda et 
al., 2007). It has been elucidated the role of miR-195 to induce heart 
failure and the role of miR-29 downregulation, following myocardial 
infarction, to increase fibrosis (van Rooij et al., 2006 and 2008). 
Several studies were also focused on the identification of miRNAs 
dysregulated during skeletal muscle regeneration and muscular 
dystrophy. Kunkel and co-workers profiled miRNAs in muscle 
samples from a variety of human patients with primary muscle 
disorders and found a collection of miRNAs commonly dysregulated 
among patients affected by different types of muscle disorders 
(Eisenberg et al., 2007). For istance, the muscle-specific miR-206 was 
found to be upregulated in regeneratin fibers from dystrophin 
deficient mice (mdx) and WT mice treated with cardiotoxin, a potent 
inducer of muscle regeneration (Yuasa et al., 2008).  The role of miR-
206 in muscle regeneration and neuro-muscular junction formation 
has also addressed in mouse models for amyotrophic lateral sclerosis 
mouse model (Williams et al., 2009).  
miRNA role was also studied in muscle neoplastic disease, like  
rhabdomyosarcoma which is caused by proliferation of muscle 
progenitor cells, where miR-29 and miR-206 act as tumor suppressor 
genes (Wang et al., 2008; Taulli et al., 2009). 
Several strategies have been developed to manipulate miRNA 
expression. A pharmacological approach is represented by the use of 
oligonucleotides which mimic miRNA sequence to overdose a 
specific miRNA or a complementary miRNA sequence to sequester it 
(Krutzfeldt et al., 2005). Also gene theraphy strategies have been 
developed to modulate miRNA expression using specific constructs 
to overexpress pri-miRNA sequences (Fati et al., 2005) or decoy 
mRNAs with artificial miRNA target sites to sequester endogenous 
miRNAs (Gentner et al., 2009).  
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Duchenne Muscular Dystrophy and gene therapy approaches 
 
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive 
disorder caused by mutations in the dystrophin gene (DMD) that 
affects 1/3500 males. This life-threatening disease is characterized by 
rapid and progressive skeletal muscle degeneration, leading to loss of 
ambulation and death. Dystrophin gene encodes for a  427 kDa 
protein that links the cytoskeleton to a complex of proteins 
(Dystrophin-Associated Protein Complex - DAPC) on the membrane 
of muscle fibers (Matsumura et al., 1994; Figure 4). The principal role 
of DAPC is to connect intracellular actin microfilaments to the 
extracellular matrix determining a structural stabilization of the 
sarcolemma (Ervasti et al., 2008). The absence of Dystrophin in 
DMD patients leads to delocalization of the entire DAPC. As a 
consequence, muscle fibers become more sensitive to mechanical 
damage leading to muscle degeneration, chronic inflammation, 
susceptibility to oxidative stress and increased fibrosis, all of which 
exacerbate the dystrophic phenotype.  
 
 
________________________________________________________ 
 
 
Figure 4. The Dystrophin-Associated Protein Complex (DAPC) 
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The majority of DMD patients carry mutations that disrupt the 
reading frame of the dystrophin gene, resulting in truncated 
dystrophin that lacks the C-terminal bridging domain (Figure 5A) 
(Aartsma-Rus et al., 2006). Interestingly, Becker muscular dystrophy 
(BMD) (Koenig et al., 1989), a milder allelic disease, is frequently 
due to mutations that maintain the DMD reading frame but result in 
an internally truncated dystrophin protein that only lacks part of the 
central rod domain. These observations have led to the concept that it 
is possible to use, either for gene replacement or in exon-skipping 
strategies, a dystrophin protein with a partially deleted flexible central 
rod domain. Indeed, several functional studies have determined that 
relatively large internal segments of the DMD gene can be deleted 
without dramatically reducing functionality (Athanasopoulos et al., 
2004). 
Over the past 20 years, the mdx mouse, carring a stop codon inside 
exon 23 of the dystrophin gene, has been widely used as animal 
model of DMD pathology. Moreover, it provides a convenient system 
to test possible therapeutic interventions and select molecular markers 
to monitor disease progression and therapeutic outcomes. 
Modifying the primary mRNA sequence is the first opportunity to 
intervene and correct mutations at the RNA level. It has been shown 
that most of the mutations in the dystrophin gene can be “cured” at 
the post-transcriptional level by preventing the inclusion of specific 
mutant exons in the mature mRNA and recovering a functional open 
reading frame (Aartsma-Rus et al., 2009). The exon-skipping strategy 
allows the production of a shorter but still functional dystrophin as a 
BMD-like phenotype. In theory, single and double exon skipping 
would be applicable to 83% of all DMD mutations (Aartsma-Rus et 
al., 2009) . The exon skypping approach was initially achieved by the 
use of antisense oligonucleotides complementary to the splice 
junctions of the exon to exclude. This successful in vitro strategy 
addresses in vivo hurdles such as whole body delivery and long-term 
expression. These issues have been improved by using expression 
cassettes to drive the expression of the antisense molecules under the 
U1 small nuclear RNA regulatory elements (Figure 5B). This 
approach was able to rescue dystrophin in cultured myoblasts from 
DMD patients (De Angelis et al., 2002) and in mdx mouse via adeno-
associated virus (AAV) delivery allowing the recovery of dystrophin 
in a body wide manner (Denti et al., 2006 and 2008). 
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A 
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Figure 5. Example of exon-skipping strategy.   
(A) Deletion of exon 50 in DMD gene results in an out-of-frame 
mRNA transcript and a prematurely aborted dystrophin synthesis. (B) 
Employing of antisense molecules against exon 51 splice sites 
produce an in frame mRNA transcript resulting in a shortened BMD-
like dystrophin protein. 
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Histone Deacetylases and Nitric Oxide in Duchenne pathology 
 
Histone deacetylases (HDACs) are a family of enzymes divided in 
four sub-classes defined according to structural similarities. They are 
principally involved in the withdrawal of acetyl-groups from a large 
number of proteins including nuclear core histones. Their pivotal role 
in regulating the acetilation state of chromatin resulted in a direct 
control of chromatin accessibility and dinamics. The presence of such 
a cohort of molecules with apparent similar enzymatic activity may 
be incorrectly interpreted as redundancy while it probably reflects 
very specialized functions. 
Due to their crucial role in epigenetic regulation of gene expression, 
HDACs have been selected as one of the first molecular targets to 
develop new epigenetically active drugs. In fact, HDAC inhibitors are 
now widely used in several cancer therapies as a consequence of their 
anti-proliferative and pro-apoptotic properties (Jung et al., 2001). 
Moreover, recent observations enlightened the important therapeutic 
effects of HDAC inhibitors in experimental animal models for 
arthritis, neurodegenerative and neuromuscular disorders, heart 
ischemia, cardiac hypertrophy, heart failure and arrhythmias 
(reviewed in Colussi et al., 2010). 
Recently, HDAC inhibitors have been found particularly effective in 
the mdx mouse model of DMD disease where they promote rescue of 
dystrophic phenotype (Minetti et al., 2006). In line with this, the same 
effect was also observed by administration of nitric oxide (NO) 
donors (Colussi et al., 2008 and 2009). 
NO has emerged as a key second messenger molecule in serveral 
cellular pathways. Its production in muscle is granted by the activity 
of a neuronal/muscular specific isoform, nNOS, which directly 
interacts with dystrophin in the DAPC. In DMD muscles the 
dystrophin absence at sarcolemma causes the mislocalization of the 
entire DAPC including nNOS and the consequent impairing in NO 
production (Brenman et al., 1995). 
Finally, a link between HDAC inhibitors and NO has been reported 
by the identification of the common cellular target, the HDAC2 
enzyme. 
While HDAC inhibitors act inactivating all members of HDAC 
family by blocking the catalityc active site,  NO inhibits specifically 
HDAC2. In fact, HDAC2 S-nitrosilation on two Cys residues 
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(Cys262 and Cys274) determines conformational changes in the 
enzyme which induce its release from chromatin and a consequent 
increase in chromatin accessibility (Nott. et al., 2008) 
In Duchenne pathology in fact, the reduction of NO production due to 
DAPC delocalization, resulted in HDAC2 S-nitrosylation-dependent 
inhibition with a consequent aberrant deacetylase activity (Colussi et 
al., 2008). 
By promoting muscle regeneration, follistatin was identified as 
HDAC2 target and it represents a mediator of therapeutic effects 
observed upon NO and HDAC inhibitors treatments (Minetti et al., 
2006). However, follistatin rescue per se is not suffcient to justify the 
global amelioration in terms of fibrosis and oxidative stress observed 
in mdx treated fibers. At the moment molecular mechanisms 
underlining physiopathology of HDAC2 action in DMD have to be 
still investigated. 
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AIMS 
 
This work started with the observation that upon dystrophin recovery 
in exon skipped treated mdx, low levels of dystrophin expression (5–
10%), are sufficient to confer a long-term benefit to the entire muscle 
from morphological and functional perspectives (Denti et al., 2006 
and 2008). So out principal aim was to study if dystrophin, beside its 
well defined structural role, could co-operate in signal transduction 
processes justifying as low protein recovery, observed upon exon 
skipping treatments, could rescue DMD phenotype almost to healty 
levels. We choose to study the role of miRNA, as putative targets of 
this suggested pathway, both in muscle fibers and muscle stem cells.  
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RESULTS 
 
The expression levels of specific miRNAs correlate with the 
amount of dystrophin  
 
Six-week old mdx animals were tail vein injected with a recombinant 
adeno-associated viral vector carrying a U1-chimeric antisense 
construct (AAV#23, Figure 6A) previously reported to induce the 
skipping of the mutated exon 23 and to restore dystrophin synthesis 
(Denti et al., 2006). After 1 month, mdx and AAV#23-treated mdx 
siblings were sacrificed in parallel with wild type (WT) isogenic/aged 
matched animals. Different muscular districts (gastrocnemius, 
diaphragm, triceps and quadriceps) were dissected and tissue 
collected for protein, RNA and chromatin analyses. Western blot 
revealed that through the exon skipping treatment, rescue of 
dystrophin was obtained in all districts (Figures 6B shows data 
relative to gastrocnemius), confirming the previously described body-
wide activity of the AAV#23 virus. Due to individual variability in 
the systemic delivery of AAV, we were able to classify injected 
animals in three different groups (G1, G2 and G3), which displayed 
≤1%, 1-5% and 5-10% of dystrophin rescue, respectively. A 
representative sample of each group is shown in Figure 6B.  
Real-time based low density arrays revealed that the expression of a 
subset of miRNAs deregulated in mdx animals, was restored towards 
WT levels in AAV#23-treated mice (data not shown). 
Among the miRNAs analyzed by array, we validated by qRT-PCR 
those showing the most prominent variations. Since homologous 
members of miR-29, miR-30 and miR-133 families were equally 
deregulated, we focused our analysis on one member per family. The 
muscle-specific (myomiR) miR-1 and miR-133 and the ubiquitous 
miR-29c and miR-30c, down-regulated in mdx, recovered towards 
WT levels in exon skipping-treated animals (shown in blue in Figure 
6C),. A direct correlation between miRNA levels and dystrophin 
rescue was observed: G1 animals showed a very limited miRNA 
recovery, while G3 displayed levels close to WT ones . 
At variance with the other myomiRs, miR-206 and miR-31 were 
highly expressed in mdx as well as in AAV#23-treated animals. 
(shown in green in figure 6C)  
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The inflammatory miR-223 (Fazi et al., 2005), specific of 
granulocytic lineage, was found to be very abundant in mdx muscles 
and proportionally reduced in the three groups of treated animals 
(shown in red in Figure 6C); its decrease in AAV#23-mdx is 
consistent with the observed amelioration of the inflammatory state of 
the muscle due to dystrophin rescue (Denti et al., 2008; Aartsma-Rus 
et al., 2009). Finally, the expression levels of the ubiquitous miR-23a 
and miR-27a were unchanged in WT and mdx, as well as in treated 
animals.  
The relative changes in the expression patterns of miR-1, miR-29, 
miR-206, and miR-223 observed in the gastrocnemius were 
confirmed in other muscle districts (data not shown), demonstrating 
that the miRNA expression profile correlated with dystrophin rescue 
in a body-wide manner.  
The observation that the expression of a specific subset of miRNAs 
varies in response to the presence of dystrophin, prompted the 
analysis in a human Duchenne model system. Differentiating DMD 
myoblasts, carrying a deletion of exons 48-50, were treated with a 
lentiviral construct expressing an antisense RNA able to induce exon 
51 skipping (LV#51) or with an empty vector (LV-mock). This 
treatment was previously shown to produce an in frame mRNA and to 
rescue dystrophin synthesis (De Angelis et al., 2002; Incitti et al., 
2010). According to the mdx model, when dystrophin synthesis was 
restored (Figure 6D), the levels of miR1, miR-133a, miR-29c, miR-
30c and miR-206 increased, while miR-23a expression did not change 
(Figure 6E).  
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Figure 6. microRNA 
expression in Duchenne 
Muscular Dystrophy. 
 (A) Schematic representation 
of the exon skipping strategy 
for mdx mutation. (B) 
Western blot with anti-
dystrophin (DYS) and anti-
tubulin (TUB) antibodies 
performed on protein extracts 
from the gastrocnemius of 
WT, mdx and AAV#23-
treated mdx (G1, G2 and G3) 
animals, sacrificed 4 weeks 
after systemic virus injection. 
Dystrophin relative 
quantifications are shown on 
the top of each lane. (C) 
Histograms show miRNA 
relative expression in WT, 
G1-G3 and mdx mice, 
measured by qRT-PCR. miR-
23a and miR-27a were used 
as controls. Expression levels 
were normalized to 
snoRNA55 and shown with 
respect to WT set to a value 
of 1. (D) Western blot with 
DYS and TUB antibodies on 
protein extracts from human 
DMD myoblasts infected 
with LV#51 (LV#51) or 
control (LV-mock) lentiviruses and differentiated for 7 days. (E) 
Histograms show miRNA relative expression in LV-mock and LV#51 
treated DMD cells measured by qRT-PCR. U6 snRNA was used as 
endogenous control. Relative expressions are shown with respect to 
LV-mock DMD cells, set to a value of 1. One asterisk (p<0.05), two 
asterisks (p<0.01). 
 
D 
E 
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HDAC2 controls the expression of specific miRNA genes 
 
Immunofluorescence analyses (Figure 7A) were performed with anti-
dystrophin and anti-nNOS antibodies on sections from the 
gastrocnemius of WT, mdx and G3 mdx (AAV#23). Upon exon 
skipping treatment, dystrophin synthesis and its correct localization to 
the periphery of the fibers was obtained (DYS); moreover, the 
restoration of dystrophin paralleled the proper co-localization of 
nNOS to the DAPC (nNOS). The morphological amelioration of the 
muscles transduced with AAV#23 was also observed by 
haematoxylin and eosin staining (data not shown). 
One interesting target of nNOS was found to be the HDAC2 
chromatin remodelling enzyme (Nott et al., 2008; Colussi et al., 
2008). Therefore, we tested whether HDAC2 was differentially 
nitrosylated in WT, mdx, and AAV#23-treated mdx animals. Protein 
muscle extracts were immunoprecipitated with anti-nitroso-cysteine 
antibody and subsequently analyzed by Western blot for HDAC2. 
The lowest level of nitrosylated HDAC2 was found in mdx mice; 
progressive increase of HDAC2 nitrosylation was detected in 
AAV#23 and WT muscles (Figure 7B). These data provided a 
correlation between nitrosylation state of HDAC2 and dystrophin 
levels. Since the nitrosylation state of HDAC2 was found to affect its 
association to the chromatin (Nott et al., 2008), we tested whether 
altered levels of miRNAs in mdx were due to HDAC2 recruitment to 
their promoters. We selected the miR-1 and miR-29 promoters since 
they have been previously characterized (Rao et al., 2006; Liu et al., 
2007; Wang et al., 2008). ChIP analysis with antibodies against RNA 
polymerase II and AcH3K9 showed low binding levels in mdx and 
progressive increase in G3 (AAV#23) and WT animals (Figure 7C). 
These data indicated a good correlation between the transcriptional 
state of these loci and the expression levels of the corresponding 
miRNAs (Figure 6C), confirming that variations in miRNA 
expression depended on transcriptional control. ChIP with anti-
HDAC2 antibody revealed its specific binding with miR-1 and miR-
29 promoters only in mdx mice (Figure 7C) where these miRNAs are 
down-regulated. No reactivity was observed with either HDAC1 or 
HDAC4 (data not shown). On the contrary, the miR-206 promoter 
(characterized by MC and DC - personal communication) did not 
reveal any HDAC2 interaction.  
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ChIP analysis were carried out also in human differentiating DMD 
myoblasts infected with the lentiviral construct expressing an 
antisense RNA (LV#51) able to rescue dytrophin synthesis. The 
results indicated that also in this system the up-regulation of miR-1 
and miR-29 correlated with release of HDAC2 from their promoters 
and changes in histone acetylation state (Figure 7D). Also in DMD 
cells no HDAC2 interaction was detected on miR-206 promoter. 
These data indicate that both in murine and human dystrophic cells 
the absence of dystrophin correlates with HDAC2 binding to a 
specific subset of miRNAs, while, upon dystrophin rescue, HDAC2 is 
released from these promoters. 
 
 
________________________________________________________ 
 
Figure 7. Dystrophin/nNOS re-localization modulates HDAC2 
occupancy on miRNA loci.  
(A) Gastrocnemius from WT, AAV#23-treated mdx and control mdx 
mice were analyzed by immunofluorescence with DYS and nNOS 
antibodies. Original magnification, X20. Scale bar 100 µm. (B) 
Protein extracts from the gastrocnemius of WT, AAV#23-treated mdx 
(AAV#23) and control mdx, were immunoprecipitated with antibody 
against nitrosylated-Cys residues and assayed for HDAC2 by Western 
blot (nitroso-HDAC2). Below each lane the relative quantities (RQ) 
with respect to WT are indicated. Values are normalized for the 
amount of total HDAC2 (HDAC2) and represent the average of three 
independent experiments.   
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(C-D) ChIP analyses performed on miR-1-2/133a, miR-29b-2/29c 
and miR-206 promoters. (C) Histograms show RNA polymerase II 
(RNAPII), AcH3K9 and HDAC2 enrichments in WT, AAV#23  and 
mdx gastrocnemius. (D) Histograms show AcH3K9 and HDAC2 
enrichments in control (LV-mock) and antisense-treated (LV#51) 
DMD myoblasts. HPRT1 and tubulin (TUB) promoter regions were 
used as unrelated transcriptional units, while 5,8S rRNA and tRNA 
genes were used as internal negative controls. Results are expressed 
as fold-enrichment of DNA immunoprecipitated samples relative to 
INPUT chromatin. One asterisk (p<0.05), two asterisks (p<0.01). 
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Nitric Oxide (NO) signalling controls miRNA expression through 
HDAC2 modification  
 
Local injection of the NO-donor nitroglycerin (NTG) was utilized as 
a way of inducing NO-response to specific body districts. Leg 
muscles of mdx animals were injected with NTG, or physiological 
solution as control, and dissected after 4 hours. Immunoprecipitation 
with antibody against nitrosylated cysteine residues and subsequent 
HDAC2 Western blot analysis, indicated that NTG treatment rescues 
the nitrosylated levels of HDAC2 to wild type values (Figure 8A). 
qRT-PCR and ChIP analysis were performed to measure miRNA 
levels and HDAC2 association to the corresponding promoters. The 
data show that NTG treatment in mdx mice: i) increases miR-1 and 
miR-29 expression (Figure 8B); ii) induces HDAC2 release from the 
promoters of these miRNAs (Figure 8C); iii) has no effect on miR-
206.  
To further prove the role of HDAC2 nitrosylation on miRNA control, 
mdx muscles were electroporated with expression cassettes encoding 
for a wild type flagged-HDAC2 protein or for a derivative mutated at 
the two cysteines (Cys 262 and Cys 274) known to be the target of 
nitrosylation (Nott et al., 2008). Two weeks after treatment, NTG was 
locally injected and samples extracted for protein, RNA and 
chromatin analyses. Figure 8D shows that both exogenous proteins 
are expressed in the electroporated tissues (Flag-HDAC2) and only 
the wild type form can be nitrosylated (nitroso Flag-HDAC2). ChIP 
experiments with anti-flag antibodies showed that, upon NTG 
treatment, wild type Flag-HDAC2 was released from miR-1 and miR-
29 promoters (Figure 8F) paralleling the increase of the 
corresponding miRNAs (Figure 8E); on the contrary, the mutant Flag-
HDAC2 protein was still associated to the promoters producing their 
down-regulation (Figure 8E and 8F). No differences were observed 
on the HDAC2-independent miR-206 promoter.  
Altogether, these results demonstrate that Nitric Oxide induces 
HDAC2 nitrosylation, thus regulating its binding on specific miRNA 
promoters.  
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Figure 8. NO 
signalling 
controls miRNA 
expression 
trough HDAC2 
nitrosylation. 
 
(A-C) mice were 
injected with 
nitroglycerin 
(NTG) into the 
right 
gastrocnemius 
and with 
physiological 
solution into the 
left one. After 4 
hours, protein, 
RNA and 
chromatin 
samples were 
collected. (A, 
right panel) 
Proteins were 
immunoprecipitated with antibody against nitrosylated-Cys residues 
and assayed for HDAC2 by Western blot (nitroso-HDAC2). Below 
each lane the relative quantities (RQ) with respect to WT are 
indicated; values are normalized for the amount of total HDAC2 
(HDAC2) and represent the average of three independent 
experiments. (B) Histograms show miRNA relative expression 
measured by qRT-PCR in NTG-treated (mdx NTG) or mock injected 
(mdx mock) mdx muscles with respect to WT one set to a value of 1. 
Relative expressions were normalized to snoRNA55. (C) ChIP 
analyses for HDAC2 on miR-1-2/133a, miR-29b-2/29c and miR-206 
promoters in WT, mdx NTG and mdx mock muscles. HPRT1 
promoter region was used as unrelated transcriptional unit while 5,8S 
rDNA was used as an internal negative control. Results are expressed 
as fold-enrichment of DNA immunoprecipitated samples relative to 
INPUT chromatin.  
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(D-F) mdx mice were 
electroporated into the 
right tibialis with 
expression cassettes 
encoding for a wild type 
flagged HDAC2 protein 
(Flag-HDAC2WT) or for 
a derivative mutated at 
Cys262 and Cys274 
(Flag-HDAC2mut). After 
2 weeks mice were 
injected with NTG into 
the right tibialis and with 
physiological solution 
into the left one (mock). 
After 4 hours protein, 
RNA and chromatin 
samples were collected. 
(D, right panel) 
Expression levels of 
flagged HDAC2 were 
assayed by Western Blot 
with anti-Flag antibody 
(Flag-HDAC2). 
Nitrosylation state was 
revealed by immunoprecipitation with anti-FLAG antibody followed 
by Western blot using an antibody against nitrosylated-Cys residues 
(nitroso-Flag-HDAC2). (E) Histograms show miRNA relative 
expression measured by qRT-PCR in mock, Flag-HDAC2WT and 
Flag-HDAC2mut treated muscles. Expression levels were normalized 
to snoRNA55 and shown with respect to mock set to a value of 1. (F) 
ChIP analyses were performed with anti-Flag antibody on miR-1-
2/133a, miR-29b-2/29c and miR-206 promoters in mock, Flag-
HDAC2WT and Flag-HDAC2mut treated muscles. Results are 
expressed as fold-enrichment of DNA immunoprecipitated samples 
relative to INPUT chromatin. Two asterisks (p<0.01).   
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miR-1 controls G6PD, a relevant enzyme in the response to 
oxidative stress 
 
In silico analysis, performed by comparing mRNA expression profiles 
in wild type versus mdx animals (Tseng et al., 2002), identified a 
large number of predicted targets of those miRNAs showing the 
highest variations in our analysis. For the down-regulated miR-1, 
miR-29 and miR-30, several up-regulated targets relevant in muscle 
physiology were found, such as those involved in energetic 
metabolism, cytoskeleton remodelling, extracellular matrix and 
transcriptional regulation in muscle (Figure 10).  
One important issue in dystrophic muscles is their susceptibility and 
response to oxidative stress suggested to be involved in disease 
progression (Rando et al., 1998). Glucose-6-Phosphate 
Dehydrogenase (G6PD) mRNA, deregulated in mdx muscles, 
contains in its 3’UTR three putative binding sites for the miR-1 
family (see Figure 9A). G6PD is a cytosolic enzyme in the pentose 
phosphate pathway that supplies reducing energy to cells by 
maintaining the level of NADPH which in turn ensures high ratio 
between reduced and oxidized glutathione (GSH/GSSG). GSH 
represents the major antioxidant molecule that protects cells against 
oxidative damage.  
Luciferase reporter assays validated G6PD mRNA as target of the 
miR-1 family. Figure S9 shows that miR-1 and miR-206, are able to 
repress luciferase activity only in the presence of a wt G6PD-3’UTR 
and that this repression is alleviated by anti-miR-1 and anti-miR-206 
LNA oligonucleotides. 
Several data indicated an inverse correlation between G6PD and miR-
1 expression: in vitro differentiation of C2 myoblasts showed that the 
increase in miR-1 levels (Figure 11A, upper panel) correlated with 
decrease of G6PD protein (Figure 11A, middle panel), and 
GSH/GSSG ratio (Figure 11A, lower panel). Figure 11B shows that 
in mdx mice, where miR-1 is down-regulated, G6PD was detected at 
higher levels than in WT muscles; whereas, in AAV#23-treated mdx, 
in which miR-1 resumes, the amount of G6PD was reduced. Notably, 
in mdx mice, increase in G6PD levels was accompanied by a decrease 
in GSH/GSSG ratio (Figure 11B, lower panel). This apparent 
contradiction can instead be explained considering that in mdx 
muscles, most of the NADPH is utilized in the O2 to O°-2 conversion 
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mediated by the Ca++-dependent activation of NADPH oxidase 
(NOX; Shkryl et al., 2009). Detoxification of the superoxide radical 
could further reduce NO levels already low in mdx. Therefore, we 
asked whether interfering with this pathway could affect the 
nitrosylation state of HDAC2. When G6PD was inactivated through 
administration of 6-aminonicotinamide (6-AN; Walker et al., 1999), 
HDAC2 nitrosylation increased as well as the levels of miR-1 (Figure 
11C). In line with this, NOX inhibition with apocynin (APO; Gupte et 
al., 2006) also increased HDAC2 nitrosylation and miR-1 levels 
(Figure 11C). Finally, G6PD down-regulation through over-
expression of miR-1 (p-miR-1) in mdx muscles increased HDAC2 
nitrosylation with respect to control (Figure 11D). The link between 
G6PD, NO, HDAC2 and miR-1 in mdx is shown in Figure 11E; 
namely, in conditions of increased levels of G6PD more O°-2 radicals, 
deriving from the activity of NOX, are converted to ONOO°-. This 
reduced both NO levels and HDAC2 nitrosylation.  
Altogether, these data demonstrate that all these components are on 
the same pathway and that a feed forward control between G6PD and 
miR-1 through the S-nitrosylation of HDAC2 exists. 
 
________________________________________________________  
Figure 9. G6PD is 
target of miR-1 family.  
(A) Luciferase reporter 
with wild type G6PD 
3’UTR or mutated for 
miR-1 target sites (B) 
Luciferase activity and 
GSH/GSSG ratios 
tested in C2 myoblasts 
in growth medium, in 
presence of miR-1 and 
miR-206 over-
expression, and in 
differentiation medium, 
in presence of LNA 
oligos against miR-1, 
miR-206 or both.  
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Figure 10.  Bioinformatics search for miRNA targets.  
mRNA microarray expression data from wild type versus mdx mice 
(Tseng et al., 2002) were analyzed searching for those species to be 
predicted targets of the miRNAs responding to the Dys-nNOS 
pathway, which were shown to be down-regulated in mdx. An ad hoc 
algoritm based on Targetscan rules was employed. For each miRNA 
analyzed, the diagram shows the number of putative targets (x axis) 
versus the logarithm of wt/mdx values (y axis).  The rectangles 
include the most up-regulated mRNAs; on the right panels, their list is 
shown selecting for those species that could be interesting for the 
Duchenne physiopathology (energetic metabolism, cytoskeleton 
remodelling, extracellular matrix, transcriptional regulation in 
muscle). Validated targets for the indicated miRNA are represented in 
red dots;  
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Figure 11. miR-1 controls 
G6PD expression.  
(A) Total RNA and protein 
extracts, from C2 
proliferating myoblasts (GM 
– growth medium) and after 
shift to differentiation 
medium (DM) for the 
indicated hours. Upper 
panels: Northern blot (miR-1 
and U2 snRNA); middle 
panels: Western blot (G6PD 
and HPRT1); lower panel: 
GSH and GSSG ratio 
obtained by enzymatic assay 
titration. (B) Total RNA and 
protein extracts from WT, 
mdx and AAV#23-treated 
mdx. Upper panels: Northern 
blot (miR-1 and snoRNA55); 
middle panels: Western blot 
(G6PD and HPRT1); lower 
panel: GSH and GSSG ratio 
obtained by enzymatic assay 
titration. (C) Upper panel: 
protein extracts, from the 
gastrocnemius of control mdx 
(mdx) and mdx treated with G6PD (6-AN) or NOX (APO) inhibitors, 
were immunoprecipitated with antibodies against nitrosylated-Cys 
residues and analyzed for HDAC2 content by Western blot (nitroso-
HDAC2). On the top of each lane the relative quantities (RQ) of 
nitroso-HDAC2 normalized for the amount of total cellular HDAC2, 
with mdx set to a value of 1, are indicated. Values are the average of 
three independent experiments. Lower panel: qRT-PCR for miR-1 on 
mdx, 6-AN and APO mdx-treated mice. Relative expressions were 
normalized to snoRNA55 and shown with respect to mdx set to a 
value of 1. (D) mdx animals were electroporated with a miR-1 
expression construct (p-miR-1) in the right gastrocnemius or with an  
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empty vector (mock) in the controlateral muscle and sacrificed after 
25 days. miR-1, G6PD and nitroso-HDAC2 levels were measured. 
Relative quantities (RQ), shown with respect to mdx set to a value of 
1, are indicated. The values are the average of three independent 
experiments. snoRNA55, ACTN and HDAC2 were used for 
normalization. (E) Pathway connecting G6PD, NOX, NO, HDAC2 
and miR-1. Two asterisks (p<0.01).   
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miR-29 controls fibrosis in mdx muscles.  
mdx animals undergo extensive fibrotic degeneration (Haslett et al., 
2002). Crucial factors involved in this event are collagens and elastin, 
structural components of the extracellular matrix, whose mRNAs 
have been recently shown to be targeted by miR-29 family in 
myocardial infarction (van Rooij et al., 2008). qRT-PCR revealed that 
in mdx, where miR-29 is poorly expressed, the mRNAs for collagen 
(COL1A1) and elastin (ELN) were up-regulated. Their amount was 
instead reduced at levels similar to WT in AAV#23-treated animals, 
where miR-29 levels were resumed (Figure 12A). In order to test 
whether miR-29 alone is able to regulate collagen and elastin mRNAs 
in the Duchenne fibrotic process, we electroporated in the 
gastrocnemius of mdx animals a plasmid DNA containing an 
expression cassette driving the transcription of the miR-29a/b cluster 
(p-miR-29). Control mdx mice were electroporated with an empty 
plasmid. 25 days after treatment, muscles were dissected and the 
presence of p-miR-29 DNA was verified by PCR (Figure 12B). 
Northern blot indicated that a 2-3 fold over-expression of miR-29 was 
specifically obtained (Figure 12C) and that this paralleled a relevant 
decrease of collagen and elastin mRNAs (Figure 12D). Trichromic 
staining on mdx mice electroporated with p-miR-29 indicated a strong 
decrease in collagen deposition (blue stain) if compared to mock-
electroporated muscles (Figure 12E). These data point to miR-29 as a 
crucial player in the control of the extracellular matrix modifications 
in mdx mice. 
 
 
Figure 12. miR-29 controls fibrosis in mdx.  
(A) qRT-PCR for collagen (COL1A1) and elastin (ELN) mRNAs 
performed on total RNA from the gastrocnemius of WT, mdx and 
AAV#23-treated mdx mice. Relative expressions were normalized to 
HPRT1 and shown with respect to WT set to a value of 1. In panels 
B-E the gastrocnemius of mdx animals were electroporated with a 
miR-29a/b expression construct (p-miR-29) and sacrificed after 25 
days in parallel with WT and a control mdx electroporated with an 
empty plasmid (mdx). (B) PCR analysis on DNA from WT, mdx and 
p-miR-29 electroporated (1-4) mdx. Primers specific for the p-miR-29 
construct and for the β-actin gene were utilized. (C) Northern blot for 
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miR-29 and control snoRNA55. Relative quantities (RQ) of miR-29, 
relative to mdx set to a value of 1, are indicated below each lane. (D) 
qRT-PCR on COL1A1 and ELN mRNAs. Relative expressions are 
normalized to HPRT1 mRNA. Values are shown with respect to WT 
set to a value of 1. (E) Masson’s trichrome staining indicates collagen 
deposition (blue stain) on p-mock and p-miR-29 electroporated mdx. 
Original magnification, X10. Scale bar 100 µm. One asterisk 
(p<0.05), two asterisks (p<0.01). 
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miR-31 and miR-206 are enriched in Duchenne muscles 
 
miR-206 and miR-31 are highly enriched in mdx mice with respect to 
control while, as already shown, miR-1 decreases (Figure 13A). 
Their abundance correlated with degeneration and regeneration 
processes, since in muscles of 10 day-old mdx, before the onset of 
dystrophic symptoms, no up-regulation was observed (Figure 13B). 
In situ hybridization (Figure 13C) showed that miR-206 and miR-31, 
almost absent in WT conditions, have a preferential co-localization in 
regenerating myoblasts MyoD+/MyoG+/MHC- (Figure 13D), 
identified by the characteristic phenotype of mononucleated fibers, 
highly abundant in mdx.  
 
_______________________________________________________
_ 
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Figure 13. miR-206 and miR-31 are expressed in regenerating 
fibers.  
(A) Representative Northern blot analysis for miR-31, miR-206 and 
miR-1 in three wild type (WT) and three mdx mice. snoRNA55 was 
used as a loading control. Fold changes are shown on the right (B) 
qRT-PCR for miR-31 and miR-206 in newborn (10d) and adult (45d) 
mdx mice. (C-D) Immunofluorescence and in situ analyses on wild 
type (WT) and mdx gastrocnemius serial sections with miR-31 and 
miR-206 DIG-labelled probes, DAPI and myosin, myoG and myoD 
antibodies. miR-31 and miR-206 positive regions lack myosin 
staining (see dashed regions in myosin panel). Original magnification 
X20, scale bar 100 µm.  
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miR-206 activates satellite cells differentiation through Pax7 
repression  
 
The differential behavior of miR-1 and miR-206 in WT versus mdx 
prompted us to analyze in more detail their pattern of expression. 
These miRNAs, while sharing the same seed, differs only for 4 
nucleotides in the 3’ portion. In situ hybridization analysis was 
performed on mdx and WT gastrocnemius by using DIG-labeled 
probes. Signals for miR-206 were restricted to immature regenerating 
fibers with centralized nuclei, whereas the miR-1 probe showed 
intense accumulation in mature differentiated fibers (Figure 14). 
Intact multi-nucleated fibers and small mononucleated cells, such as 
inflammatory cells, fibroblasts and proliferating satellite cells lacked 
the miR-206 signals (note the absence of signals in interstitial 
spaces). Therefore, increased expression of miR-206 in mdx muscles 
is due to differentiating satellite cells. 
Next, we isolated mouse satellite cells from muscle biopses and 
differentiated them in vitro (Rando and Blau, 1994). miR-206 
expression was activated at 12 hours and its accumulation proceeded 
during differentiation (Figure 15A, upper panel). Notably, the 
satellite-specifying factor Pax7 (Relaix et al., 2006), abundant in 
growth conditions, started to decrease at 12 hours and completely 
disappeared at 24 hrs, therefore showing an inverse correlation with 
miR-206 levels (Figure 15A, lower panel). Moreover, transfection of 
in vitro cultured satellite cells with anti-miR-206 LNA 
oligonucleotides indicated that in the absence of miR-206, Pax7 
repression was unaffected at 12 hours and remained detectable up to 
48 hours (Figure 15B). The link between Pax7 decrease, miR-206 
induction and the presence of miR-206 putative target sites in the 
3’UTR of Pax7 mRNA (Figure 15C) led us to study whether a 
regulatory interaction exists. Wild type Pax7 3’UTR and its mutant 
for miR-206 binding sites were cloned downstream Renilla ORF and 
reporter constructs were tranfected in C2 myoblasts. Luciferase 
assays show that reporter downregulation, in condition of miR-206 
overexpression is achieved only on WT-3’UTR (Figure 15D). These 
experiments indicated that Pax7 can be repressed also by miR-1; 
however, as shown in the Northern of figure 15A, in cultured satellite 
cells miR-1 is almost undetectable at 12 hours when down-regulation 
of Pax7 starts, allowing to conclude that mainly mir-206 is expressed 
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at a time compatible with Pax7 repression. Therefore, these data 
demonstrates that miR-206 plays a specific role in early events of 
regeneration by repressing the activity of Pax7 thus allowing the 
progression of the differentiation program. 
ChIP analysis for HDACs binding on the miR-1 and miR-206 loci in 
conditions of miRNA repression (GM - growth medium) versus 
miRNA activation (DM - differentiation medium) in C2 myoblasts 
indicated that, differently from miR-1, miR-206 is specifically 
repressed by HDAC1 (Figure 15E and F). The restricted expression 
of miR-206 in early phases of differentiation, before dystrophin 
synthesis starts, well correlates with its expression being unaffected 
by the Dys/nNOS/HDAC2 pathway.  
 
 
 
 
 
 
________________________________________________________ 
 
Figure 14. differential expression of miR-1 and miR-206. A miR-1 
or miR-206 DIG-labelled probe was hybridized on mdx 
gastrocnemius sections. Original magnification, X20. Scale bar 50 
µm. 
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Figure 15. Pax7 is target of miR-206. 
(A) RNA and protein samples were extracted from proliferating 
satellite cells (GM – growth medium) and after shift to differentiation 
medium (DM) for the indicated hours. Upper panels: Northern blots 
for miR-206, miR-1 and snoRNA55; lower panels: Western blots for 
PAX7, myogenin (MYOG), dystrophin (DYS) and tubulin (TUB). 
(B) Western blot for PAX7 on protein extracts of murine satellite 
cells transfected with anti-miR-206 or scramble LNA oligos in GM 
and switched to DM for the indicated hours. Ponceau staining was 
used as loading control. (C) Luciferase reporter with wild type (WT) 
Pax7 3’UTR or mutated for miR-206 target sites (D) Luciferase 
activity in C2 myoblasts in growth medium, in presence of miR-1 or 
miR-206 over-expression. (E) miR-1, miR-206 and U2 snRNA 
expression analyzed by Northern blot in C2 myoblasts maintained in 
GM or in DM for 5 days. (F) ChIP analysis on miR-1-2/133a and 
miR-206 promoters with antibodies against AcH3K9, HDAC2 and 
HDAC1 on chromatin from C2 cells in GM and DM. 5,8S rDNA was 
used as internal negative control. Results are expressed as fold-
enrichment of DNA immunoprecipitated samples relative to INPUT 
chromatin. Two asterisks (p<0.01). 
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miR-31 is expressed in DMD myoblasts delayed in differentiation 
 
Also in human DMD biopsies, miR-31 was more abundant if 
compared to healthy and Becker muscles (Figure 16A). miR-31 
remained high in DMD myoblasts induced to differentiate in vitro, 
whereas in human healthy controls its levels decreased with 
progression of differentiation (Figure 16B). DMD myoblasts 
appeared to have a higher proliferating capacity and a lower 
differentiation potential than control cells. This was shown by the 
presence of PAX7 in growth conditions and by the delayed 
appearance of differentiation markers upon serum withdrawal (Figure 
16C). In control myoblasts, myogenin peaked already at day 2 of 
differentiation, preceding myosin heavy chain and dystrophin 
synthesis; whereas in DMD cells, myogenin appeared only at day 4 
preceding MHC synthesis, clearly visible at day 6. Immunostaining 
of the same samples confirmed that DMD cells express MHC protein 
at lower levels and later than Ctrl cells (Figure 16C and D). 
These data, together with results in Figure 13 indicate that the high 
levels of miR-31 in Duchenne muscles is due on one side to intensive 
regeneration involving activated satellite cells and on the other to the 
reduced ability of Duchenne myoblasts to complete the differentiation 
programme.  
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Figure 16. miR-31 is expressed in delayed DMD myoblasts. (A) 
qRT-PCR of miR-31 relative expression in human muscle biopsies 
from healthy (Ctrl), Duchenne (DMD) and Becker (BMD) donors. 
(B) qRT-PCR of miR-31 relative expression in human primary 
myoblasts from healthy donors (Ctrl, black bars) or DMD patients 
(DMD, grey bars) in growth medium (GM) and at the indicated time 
points after shift to differentiation medium. (C) The same cells were 
analyzed by Western blot for PAX7, myogenin (MyoG), Myosin 
Heavy Chain (MHC) and Dystrophin (DYS).  Actinin (ACTN) was 
used as a loading control. The values are derived from at least three 
independent experiments. Asterisks: p<0.05. (D) 
Immunofluorescence staining with MHC antibodies (red) and DAPI 
(blue) on Ctrl and DMD myoblasts at 4 days after induction of 
differentiation. 
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miR-31 targets dystrophin mRNA 
 
In silico analysis, performed by comparing mRNA expression 
profiles in wild type versus mdx animals (data not shown), identified 
a large number of predicted targets of miR-31. Notably, the most 
down-regulated mRNA in mdx muscles encode for proteins involved 
in terminal differentiation, including dystrophin. One putative binding 
site, embedded in a 40 nucleotide region perfectly conserved among 
mammalian species, was identified in the 3’UTR of the dystrophin 
mRNA (Figure 17A). Wild type dystrophin 3’UTR (DMD-WT) and a 
derivative mutated in the miR-31 target site (DMD-mut) were fused 
to the luciferase ORF (Figure 17B). Enzyme activity was measured in 
C2 myoblasts in endogenous conditions and upon miR-31 
overexpression (Figure 17C). The results indicate that miR-31 
repressed luciferase activity only on DMD-WT and that de-repression 
was obtained with LNA oligos against miR-31 and not with control 
scramble LNA. Scramble LNA transfection per se did not affect 
luciferase activities (not shown). Moreover, when cells were treated 
with a sponge-construct containing four binding sites for miR-31 
(Sponge-31, Figure 17A and B), luciferase activity resulted higher 
with respect to cells treated with a control construct (Figure 17D). 
Release from miR-31 repressing activity was also obtained when cells 
were treated with a LNA oligo complementary to 23 nucleotides 
across the miR-31 target site (protector-31) both in the presence of 
the endogenous miR-31 and in conditions of miR-31 overexpression 
(Figure 17E).  
These data indicate that miR-31 targets the 3’UTR of the dystrophin 
mRNA and that repression is prevented either by the use of miR-31 
decoys or by protecting the miR-31 binding site on dystrophin 
mRNA.    
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Figure 17. miR-31 targets Dystrophin mRNA.  
(A) Sequences of: the mature miR-31, the conserved 40 nucleotide 
region of the DMD 3’UTR, the decoy sequence of the sponge-31 
construct and the 23 nucleotide LNA protector (Protector-31) 
covering miR-31 binding site on the DMD 3’UTR. miR-31 seed 
sequence is underlined. (B) Schematic representation of: the 
luciferase constructs containing the wild type 3’UTR of the 
dystrophin mRNA (DMD-WT) and its mutant derivative with a 
deletion of the miR-31 target site (DMD-mut), the sponge constructs 
containing the GFP gene with a control 3’UTR (Sponge-Ctrl) or with 
the same 3’UTR containing four miR-31 decoy sites (Sponge-31). (C) 
Renilla Luciferase activity in proliferating C2 myoblasts transfected 
with the control Rluc vector or DMD-WT or DMD-mut. in 
combination with the plasmid overexpressing miR-31 (pmiR-31) or a 
control plasmid (Ctrl). Cells were also transfected  with control 
(LNA-Scr) or anti-miR-31 (LNA-31) LNA oligos. Renilla activity of 
the Rluc vector was set to a value of 100% in all treatments. (D) 
Renilla Luciferase activity in C2 myoblasts transfected with DMD-
WT, in the presence of Sponge-Ctrl or Sponge-31 constructs, with 
pmiR-31, or a control plasmid. (E) Renilla Luciferase activity in C2 
myoblasts transfected with DMD-WT alone (Ctrl) or upon miR-31 
overexpression (pmiR-31) in the presence of control (LNA-Scr) or 
protector (Protector-31) LNAs. The values of all experiments are 
derived from at least three independent experiments. Asterisks: 
p<0.05.
Davide Cacchiarelli 
Pag. 48  
miR-31 inhibition enhances exon skipping treatment 
 
In vitro differentiation of C2 mouse myoblasts indicated that miR-31 
was expressed at good levels in proliferating conditions (GM) and its 
levels decreased upon differentiation (Figure 18A). Synthesis of 
dystrophin was prominent only at day 5 even though transcription 
was already consolidated at day 3. These data reflected the expected 
inverse correlation between the miRNA and its putative target. We 
next tested in C2 myoblasts whether the endogenous synthesis of 
dystrophin correlated to altered levels of miR-31 (Figure 18B): 
overexpression was obtained through infection with a lentivirus 
containing the pri-miR-31 expression cassette (miR-31), while 
depletion was obtained via administration of  LNA-31 or sponge-31. 
When cells were induced to differentiate, a consistent decrease of 
dystrophin (almost 3-fold) was observed in conditions of persistent 
overexpression of miR-31; on the contrary, increase in dystrophin 
levels was detected when cells were treated with LNA-31 or sponge-
31. In the last two cases, the limited increase (50 and 40% 
respectively) of dystrophin synthesis is likely due to the fact that 
miR-31 levels already start to decrease at 3 days of differentiation 
(Figure 18A).  In the lower panels of Figure 18B the levels of the 
dystrophin protein are compared with those of its mRNA; in all cases 
dystrophin mRNA levels were not affected by miR-31 modulation, 
indicating that the miRNA acts by repressing translation rather than 
controlling dystrophin mRNA stability. 
DMD myoblasts, from patient with deletion of exons 48-50, were 
infected with the U1#51 construct able to induce skipping of exon 51 
and to rescue dystrophin synthesis (Figure 18C and D; Incitti et al., 
2010). In order to check whether dystrophin synthesis could be 
further improved by reducing miR-31 levels, we tested the ability of 
the sponge-31 construct to increase dystrophin levels when infected in 
∆48-50 DMD myoblasts. Figure 18D shows that sponge construct 
was indeed able to increase by 3-fold dystrophin synthesis when exon 
skipping was applied to these cells. Moreover, also the anti-miR-31 
LNA oligos were able to increase dystrophin synthesis (2-fold) when 
transfected into exon skipping-treated cells. qRT-PCR showed that 
dystrophin mRNA levels were the same in the different conditions, 
similarly to the MCK mRNA.  
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Figure 18.  Effects of miR-31 modulation on dystrophin 
expression. (A) Northern (miR-31 and U2) and Western (DYS and 
ACTN) analyses of C2 mouse myoblasts in growth medium (GM) 
and at 3 and 5 days after shift to differentiation medium. The 
histogram at the bottom shows the relative quantification (RQ) of 
dystrophin protein and mRNA levels referred to the 3 day point set to 
a value of 1. (B) Northern (miR-31 and sno55) and Western (DYS 
and ACTN) analyses on C2 myoblasts treated with: lentiviruses with 
control (Ctrl) or miR-31 (miR-31) expression cassettes, control 
(LNA-Scr) or anti-miR-31 (LNA-31) LNA oligos and lentiviruses 
carrying Sponge-Ctrl or Sponge-31. Differentiation was allowed to 
proceed for 3 days. Dystrophin mRNA (DYS mRNA, black bars) and 
protein (DYS protein, white bars) levels were measured from three 
independent experiments. Histograms at the bottom show the relative 
quantifications (RQ) of dystrophin protein and mRNA levels referred 
to the values of control experiments (Ctrl, LNA-Scr and Sponge-Ctrl) 
set to 1.  
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(C) Schematic representation of the exon skipping strategy for the 
human ∆48-50 DMD mutation. (D) human ∆48-50 DMD myoblasts 
were infected with control (mock) or U1#51 lentiviruses alone or in 
combination with the miR-31 sponge (U1#51 Sponge-31). 
Alternatively, cells treated with the exon skipping construct (U1#51) 
were transfected with control (LNA-Scr) or anti-miR-31 (LNA-31) 
LNA oligos. Cells were induced to differentiate for 5 days and 
dystrophin quantified by Western blot. Histograms show the RQ of 
dystrophin protein and mRNA levels as well as MCK mRNA levels 
respectively referred to the values of control experiments set to 1. 
Asterisks: p<0.05. 
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DISCUSSION  
 
In Duchenne Muscular Dystrophy, muscle fiber breakage and 
degeneration, due to the absence of dystrophin, are accompanied by a 
complex series of events including activation of satellite cells, 
inflammatory infiltration, intense fibrosis and oxidative stress. These 
pathogenetic features are ameliorated in mdx mice in which 
dystrophin is rescued through different therapeutic strategies 
(Aartsma-Rus et al., 2009). Surprisingly, the beneficial effects 
observed on muscle function and morphology could be obtained also 
with low levels of rescued protein (Denti et al. 2008; Ghahramani 
Seno et al., 2008), suggesting that partial protein re-localization to the 
membrane could be only part of the story. Dystrophin has been 
suggested to affect gene expression through activation of the NO 
pathway and HDAC2 regulation (Colussi et al., 2009); however, no 
specific genes and regulatory circuitries that could account for the 
observed morpho-functional benefits had been characterized. In this 
work, taking advantage of the exon skipping strategy, we identified a 
specific group of miRNAs whose expression depends on dystrophin 
levels and whose de-regulation explains several DMD pathogenetic 
traits. This class of miRNAs, poorly expressed in mdx, was up-
regulated in exon skipping-treated animals and included muscle 
specific (miR-1 and miR-133) and more ubiquitous (miR-29 and 
miR-30) ones. The same miRNAs displayed a dystrophin-dependent 
up-regulation also in human DMD myoblasts rescued for dystrophin 
synthesis through exon skipping.  
The transcriptional activation of these miRNAs correlated with the 
acetylation state of H3K9 and modulation of HDAC2 binding to their 
promoters: in absence of dystrophin, the low miRNA expression 
levels paralleled persistence of HDAC2 onto miRNA regulatory 
regions. On the contrary, when dystrophin synthesis was rescued, 
HDAC2 was released from miRNA promoters and their transcription 
resumed.  The use of mutated HDAC2 as well as treatment of mdx 
mice with NO-donors (NTG) indicated that the release of HDAC2 
from chromatin was due to its nitrosylation. Notably, we showed that 
as a consequence of dystrophin rescue, nNOS was stabilized and re-
localized on the muscle membrane and this directly affected the 
nitrosylation levels of HDAC2. Altogether, these data allowed us to 
conclude that Dystrophin, nNOS, HDAC2 nitrosylation and miRNAs 
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are on the same regulatory pathway as indicated in the model of 
Figure 19. 
Analysis of the targets of the modulated miRNAs underscored 
regulatory networks important for understanding the DMD 
physiopathology. One relevant discovery was the finding that miR-1 
controls the Glucose 6-Phosphate Dehydrogenase (G6PD), an 
housekeeping enzyme encoded in mammals by an X-linked gene. 
G6PD has important functions in intermediary metabolism because it 
catalyzes the first step in the pentose phosphate pathway and provides 
reductive potential in the form of NADPH; in fact, through NADPH 
production, G6PD is required to maintain cytosolic GSH levels and to 
protect against free radical injury. Disruption of the G6PD gene in 
male mouse embryonic stem cells indicated that G6PD activity is 
dispensable for pentose synthesis, but is essential to protect cells 
against even mild oxidative stress (Pandolfi et al., 1995). At variance 
with normal muscles, in degenerating fibers most of the NADPH 
produced is utilized in the O2 to O°-2 conversion mediated by the 
Ca++-dependent activation of NADPH oxidase (NOX; Gupte et al., 
2006; Shkryl et al., 2009), suggesting that in dystrophic fibers G6PD 
may have an aberrant action in radical production. Indeed, in mdx 
fibers higher expression levels of NADPH oxidase were detected 
(Shkryl et al., 2009), suggesting a major contribution of this enzyme 
to the well documented oxidative stress occurring in these damaged 
muscles. Moreover, dystrophin-deficient cells were shown to be more 
susceptible to free radical induced injury if compared to normal cells, 
even though the two populations were equally susceptible to other 
forms of metabolic stress (Rando et al., 1998). 
In line with these data, we demonstrated that while miR-1 was able to 
down-regulate G6PD, decreasing the levels of GSH in normal 
muscles, in dystrophic ones the increase in G6PD did not correlate 
with GSH levels.  In mdx muscles, where the NADPH oxidase (NOX) 
undergoes up-regulation, most of the NO pool is utilized to convert 
superoxide species (O°-2) into peroxinitrite (ONOO-); indeed we show 
that under these conditions HDAC2 is poorly nitrosylated, paralleling 
miR-1 repression and G6PD up-regulation. Exogenous modulation of 
this pathway, through G6PD or NOX inhibition, had consequent 
effects both in increasing HDAC2 nitrosylation and miR-1 up-
regulation. Finally, local over-expression of miR-1 in mdx muscles 
determined down-regulation of G6PD and in turn increase of HDAC2 
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nitrosylation. Altogether these data proved the existence of a feed 
forward circuitry between G6PD and miR-1 through nitrosylation of 
HDAC2 (Figure 11E) and suggested that the regulatory network 
dependent on the dys/nNOS pathway has physiological relevance in 
controlling also the oxido-reductase state of the injured muscle. 
The relevant role of the identified dystrophin-dependent miRNAs in 
the DMD pathogenesis was also tested for mir-29. Its over-expression 
in the gastrocnemius of mdx animals indicated that not only the target 
mRNAs for collagen and elastin were specifically down-regulated, 
but also that the muscles recovered a phenotype with a strong 
reduction in fibrosis.  
These findings show a new link between the dystrophin/nNOS 
pathway and important molecular circuitries, including specific 
miRNAs and their targets, which play an important role in muscle 
differentiation, homeostasis and integrity (Figure 19).  
 
 
At variance with the other myomiRs, mainly present in mature fibers, 
miR-206 and miR-31 were restricted to differentiating satellite cells; 
therefore, their higher levels in mdx and exon skipping-treated 
animals were due to massive regeneration occurring in dystrophic 
muscles. The compartmentalized expression observed in vivo was 
confirmed in cultured satellite cells where miR-206 was shown to 
repress Pax7. This transcriptional factor, which is the mark of 
myogenic progenitor cells, has been described to regulate self-
renewal of satellite cells and their entry into the program of skeletal 
muscle differentiation (Figure 20; Buckingham and Relaix, 2007).  
Moreover, miR-206 differed from miR-1, also because it was shown 
to be under the HDAC1 control. This, together with the restricted 
expression in activated satellite cells before the onset of dystrophin 
synthesis, is consistent with the finding that miR-206 is independent 
from the dys/nNOS pathway active in mature differentiated fibers. 
These data disclose a different function for the two members of the 
miR-1 family and provide a molecular mechanism for understanding 
how the switch between proliferation and differentiation of satellite 
cells can be obtained.  
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Figure 19. Model of 
the pathway con-
necting dystrophin to 
specific miRNA 
genes. 
In WT muscle fibers 
the dystrophin-DAPC 
complex activates 
nNOS and S-
nitrosylation of 
HDAC2. The 
modified HDAC2 is 
released from 
chromatin and 
activation of a specific 
subset of miRNA 
occurs. In Duchenne 
Muscular Dystrophy 
this circuitry is 
deregulated due to 
impaired nNOS 
activity and decrease 
in HDAC2 
nitrosylation causing 
its retention to 
miRNA promoters.  
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The differential regulation of miR-1 and miR-206 also suggests that 
the epigenetic control mediated by the late differentiation marker, 
dystrophin, is important for increasing the robustness of the muscle 
differentiation programme consolidating the expression of those 
miRNAs involved in circuitries of terminal differentiation and tissue 
integrity.  
 
In line with this, we described miR-31 as part of circuitries 
controlling late muscle differentiation by repressing dystrophin 
synthesis and, likely, many other terminal differentiation markers. 
miR-31 was previously described to repress myf5, a key element of 
muscle differentiation, both in muscle and brain (Daubas et al., 
2009).   
miR-31 repressing activity was detected in early phases of myoblasts 
differentiation supporting the idea that this control is necessary in 
normal muscle cells to avoid early expression of late differentiation 
markers and, specifically, dystrophin. 
The intense and localized expression of miR-31 in regenerating 
myoblasts of dystrophic muscles indicated that the high levels of 
miR-31 found in dystrophic conditions (both in mouse and human 
biopsies) are due to the intensive regeneration program which is 
mediated by the activation of satellite cells. Interestingly, in 
dystrophic myoblasts and satellite cells the lack of dystrophin 
correlated with a delay of the maturation process of the cells.  
In this study we have also shown that in dystrophic conditions, when 
dystrophin synthesis is rescued through the exon skipping strategy, 
the inhibition of miR-31 activity increased dystrophin production. 
Since in a compromised muscle the contribution to dystrophin 
production by regenerating fibers is quite relevant, miR-31 repression 
in this compartment can represent an improvement to current 
therapeutic treatments aimed to increase the levels of dystrophin 
synthesis. Rescue of consistent levels of dystrophin will also have 
additional benefits such as the completion of the muscle fiber 
maturation process (Figure 20). 
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Figure 20. miR-206 and miR-31 regulate muscle regeneration. 
miR-206 and miR-31 are expressed in differentiating satellite cells 
where miR-206 represses Pax7 allowing differentiation to proceed 
and miR-31 inhibits dystrophin avoiding its early expression. 
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MATERIALS AND METHODS 
 
Animal treatments and constructs. 6 week-old mdx mice were tail 
vein injected with 0.5-1x1012 genome copies of the AAV-U1#23 
(AAV#23) or virus as described in Denti et al. (2006) and sacrificed 
after 4 weeks. Electroporation was performed on 6 week-old mdx as 
described  in Donà et al. (2003). Wild type and mutant FLAG-
HDAC2 plasmids provided by Dr A. Riccio and described in Nott et 
al. (2008). Nitroglycerin treatments were performed on 6-18 weeks-
old mdx mice by local injections of 0,3 mg/kg of nitroglycerin or 
physiological solution in tibialis or gastrocnemius muscles and 
sacrificed after 4 hours. Apocynin and 6-aminonicotinamide were 
administered to mdx mice by osmotic pumps (ALZET) as in Walker 
et al. (1999) and Gupte et al. (2006). 
Cell culture. Muscle satellite cells were cultured and differentiated as 
described in Rando and Blau (1994). The Duchenne primary 
myoblasts carrying exons 48-50 deletion were obtained from 
Telethon Biobank (Carlo Besta Institute, Milan), and infected with a 
lentiviral construct containing antisense sequences against the splice 
junctions of exon 51 (LV#51, Incitti et al, 2010). LNA miRNA 
Knockdown (Exiqon) treatment were performed according to Taulli 
et al. (2009). 
Protein and miRNA in situ analyses. Western blot on total extracts, 
H&E staining and in situ analyses on 7 µm-thick gastrocnemius 
cryosections were performed as described in Denti et al. (2006). In 
situ hybridizations were performed with NCL-DYS2 (Novocastra), 
nNOS, myoD, myoG, MHC (Santa Cruz). Immunoprecipitations on 
protein extracts were performed with antibody against S-nitroso-Cys 
(Sigma) according to manufacturer’s specifications and revealed by 
Western blot using an antibody against HDAC2 (Upstate). Masson’s 
Trichrome staining (Sigma) was performed according to 
manufacturer’s specifications. miRNA in situ hybridization was 
performed in formaldehyde and EDC-fixed gastrocnemius 
cryosections according to Pena et al. (2009). 
Chromatin immunoprecipitation assays. ChIP analysis was 
performed according to Ballarino et al., (2005) with the following 
antibodies: HDAC2 and RNA Pol II (Santa Cruz), HDAC1, HDAC4, 
acetylated H3-Lys9 (Upstate) and FLAG (Sigma). The starting 
material was 1-3mm3 for tissue samples or 1-10x105 cultured cells. 
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ChIP assays on DMD cells were performed using the EZ Magna ChIP 
Assay Kit (Millipore) following manufacturer’s specifications. 
RNA preparation and analysis. Total RNA was prepared from 
liquid nitrogen powdered tissues homogenized in Qiazol reagent 
(QIAGEN). miRNA and mRNA analyses were performed using 
miScript System (QIAGEN). Relative quantification was performed 
using as endogenous controls U6 snRNA for miRNAs and HPRT1 for 
mRNAs. Northern blots for miRNAs were performed using LNA 
detection probes (Exiqon).  
Luciferase constructs and assays. Full length murine 3’UTR 
sequences of G6PD, PAX7 and DMD were amplified by PCR and 
then cloned in Not I restriction site of the psicheck2 plasmid 
(Promega), downstream the renilla luciferase (RLuc) gene. The same 
plasmid contains also the firefly luciferase (FLuc) to normalize 
transfection efficiency. Mutant derivative were obtained by deletion 
of miRNA binding sites by inverse PCR. RLuc and FLuc activities 
were measured by Dual Glo luciferase assay (Promega).  
GSH/GSSG. GSH and GSSG titration were performed by 
fluorimetric assays (Biovision) according to manufacturer’s 
specifications. 
miRNA overexpression and sponge constructs. miRNA 
overexpression constructs were produced by cloning pri-miRNA 
sequences, with 100 nucleotides upstream and downstream the pre-
miRNA, into the U1snRNA expression cassette (according to Denti et 
al., 2004). Sponge-31 construct was generated by cloning annealed 
oligonucleotides containing four miR-31 artificial binding sites into 
the WPRE SacII restriction site downstream the GFP open reading 
frame according to Gentner et al. 2009. miR-31 sponge was combined 
with exon skipping by cloning annealed oligos into the WPRE 
sequence of GFP reporter of lentiviral PCCL-U1#51 reported to 
induce skipping of DMD exon 51 (Incitti et al., 2010).  
Statistical analyses. Each data shown in histograms is the result of at 
least three independent experiments performed on at least three 
different samples/animals. Data are shown as mean ± standard 
deviation. Unless specifically stated, statistical significance of 
differences between means was assessed by two-tailed t-test and a p < 
0.05 was considered significant. 
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